

## FREE AMINO ACIDS IN BLOOD PLASMA OF PATIENTS WITH MYOCARDIAL INFARCTION

*Małgorzata Knap<sup>1\*</sup>, Dorota Maciąg<sup>2</sup>, Karolina Knap-Czop<sup>3</sup>, Marcin Czop<sup>3</sup>, Jacek Janowski<sup>4</sup>, Janusz Kocki<sup>3</sup>*

<sup>1</sup> Faculty of Medicine and Health Sciences, Jan Kochanowski University, Kielce, Poland

<sup>2</sup> College of Business and Entrepreneurship in Ostrowiec Świętokrzyski, Poland

<sup>3</sup> Department of Clinical Genetics, Medical University in Lublin, Poland

<sup>4</sup> Department of Emergency Medicine, Faculty of Medicine and Health Sciences, Jan Kochanowski University, Kielce, Poland

\*Corresponding author e-mail: malgoknap@gmail.com

**S u m m a r y.** Myocardial infarction (MI) is a pathological condition resulting from total occlusion of coronary blood supply to some part of the heart muscle. This causes necrosis of the heart muscle of various extent. The most frequent background of the development of myocardial infarction is coronary atherosclerosis. The majority of patients with coronary atherosclerosis experience ischemia during effort and a characteristic chest pain. Free amino acids (AAs) play an important role both in human physiology and pathology. The pool of free amino acids varies, because amino acids are supplied to this pool, as well as uptaken and used as needed by the body. MI poses a direct life threat as it considerably affects other body functions, and changes blood serum free amino acids concentrations. The objective of the study was determination of the level of free amino acids profile in patients with MI, and assessment of the level of free amino acids in patients with MI under the age of 65, and 65 years old and older. MI as a life threatening state causes dynamic changes in free amino acid profile; however, this is more significant in the patients aged over 65. On day 0 in the group of patients  $\geq 65$  the level of amino acids was statistically significantly higher, however it decreased during the rest of the observation period.

**K e y w o r d s:** cardiovascular diseases, age, amino acid profile

### INTRODUCTION

Over the centuries, people have recognized factors causing diseases and learnt to diagnose and cure them. The introduction of mandatory protective vaccinations has minimized the epidemic of dangerous infectious diseases which have threatened mankind. The symptoms of heart disease in the form of

angina pectoris were already known to physicians in ancient times. Galen Claudius, a Roman doctor, referred clinical symptoms of the disease to the organ, naming angina pectoris 'cardialgia' [3, 6]. Scientific observations concerning the relationship between economic status and morbidity due to cardiovascular diseases conducted over the years initially indicated a higher risk of coronary disease in individuals with a high socio-economic status (SES). Cardiovascular diseases were perceived not only as a consequence of improved life standard and prosperity, but also as a model clinical problem resulting from the modernization of societies enjoying better life [30]. Poland is characterized by an especially unfavourable situation with respect to the occurrence of cardiovascular diseases and their risk factors. Therefore, the problem of prevention of cardiovascular diseases has become one of the most important tasks aimed at the reduction of morbidity due to heart diseases, the complication of which is myocardial infarction [4, 25, 27].

Myocardial infarction is a pathological condition resulting from total occlusion of coronary blood supply to some part of the heart muscle. This causes necrosis of the heart muscle affecting an area of various extent. The most frequent background of the development of myocardial infarction is coronary atherosclerosis. Myocardial infarction and its consequences are the main cause of deaths not only in Poland, but worldwide [6, 14, 17].

In the majority of cases, the direct cause of myocardial infarction is a total occlusion of the lumen of the coronary artery, most frequently caused by intravascular thrombus due to the detached atherosclerotic plaque. In 90% of cases, atherosclerosis is the primary cause of MI. Also critical cardiac ischemia which lasts too long (longer than 30 minutes) leads to myocardial infarction [9, 21, 28, 31].

Another cause of infarction is a sudden increase in the demand of the heart muscle for oxygen with the existing impairment of the coronary flow reserve, i.e. the capacity for an adaptive increase in the blood flow through the coronary arteries. The condition is escalated when the sympathetic nervous system is stimulated by physical effort, acute pain, psychological stress, shock, thyroid storm, considerable acceleration of the heart rate, elevated body temperature, and an abrupt withdrawal of drugs blocking beta adrenergic receptors. Thus, myocardial infarction is the complication of a severe form of ischemic coronary disease [13, 18, 29].

Proteins are organic compounds indispensable for the existence of a cell. They are of decisive importance for biochemical processes which are the essence of all life functions [15, 22]. Proteins are not only the essential elements of the cell structures, but also the factors controlling biological transformations in the body. Both structural proteins and proteins regulating biochemical processes in the body wear out and are subjected to degradation. Amino acids (AAs) are the structural units of proteins and peptides. They contain two functional groups, i.e. an amino group and a carboxyl group. Therefore, they may bind together by peptide bonds. Amino acids are necessary for the formation of biologically active amines, neurotransmitters, hormones, hem, or purines [8, 15, 16].

In the cells, proteins are constantly renovated in a continuous process of degradation, and subsequent re-synthesis from free amino acids. Free amino acids, which are present in the organisms of humans and animals, constitute the so-called 'pool of free amino acids'. They may originate from alimentary proteins, decomposition of the body's own proteins, synthesis of endogenous amino acids, or conversion into other amino acids [24]. Many pathological processes, such as pancreatitis or septic states of various origin impair body homeostasis [5]. Free amino acids play an important role, both in human physiology and pathology. The pool of free amino acids varies, because amino acids are supplied to this pool and used as needed by the body. Cardiovascular diseases such as myocardial infarction exert an effect on the functioning of the whole body. They may also affect

protein metabolism, especially changes in the level of free amino acids in the blood plasma.

## AIM OF THE STUDY

The objectives of the study were:

1. determination of the level of free amino acids in patients with MI,
2. evaluation of the level of free amino acids in the examined patients with myocardial infarction aged under 65, and 65 years and older.

## MATERIALS AND METHODS

The clinical material for the conducted study was the blood collected from the patients treated for MI. The blood was taken from the cubital vein four times: on admission to hospital (day 0), and subsequently on the first, third and seventh day of hospitalization. Blood was taken from the cubital vein fasting, in the morning hours; 5 ml of blood was collected into a test tube, and left at the temperature of 4°C until thrombus formation. Subsequently, the blood was centrifuged at 3,000 x g for 15 minutes in order to separate the plasma. From the centrifuged plasma, proteins were removed using 6% sulphosalicylic acid. The levels of free amino acids in the supernatant obtained were determined by ion exchange chromatography method using an automatic amino acid analyzer AAA 400-INGOS (Prague, The Czech Republic).

### Characteristics of the study groups.

The study was conducted in the group of 128 patients, 88 males (68.75%) and 40 females (31.25%), aged 48–83 (mean age of males 62.43, and females – 66.35), hospitalized for myocardial infarction in the Świętokrzyskie Cardiology Centre in Kielce (Table 1). The examined patients were divided into two groups: group 1 – patients under 65yrs, and group 2 – patients 65 years old and older (Table 3).

Table 1. Characteristics of the examined group.

| Gender  | No. of patients | %      | No. of patients < 65yrs | %      | No. of patients ≥ 65 yrs | %      |
|---------|-----------------|--------|-------------------------|--------|--------------------------|--------|
| Males   | 88              | 68.75% | 50                      | 92.32% | 38                       | 60.32% |
| Females | 40              | 31.25% | 15                      | 23.08% | 25                       | 39.68% |
| Total   | 128             | 100%   | 65                      | 100%   | 63                       | 100%   |

Table 2. Age of the examined patients.

| Gender  | M     | SD    | Min | Max |
|---------|-------|-------|-----|-----|
| Males   | 62.43 | 9.75  | 48  | 78  |
| Females | 66.35 | 12.27 | 50  | 83  |
| Total   | 63.81 | 10.76 | 48  | 83  |

### Analysis of amino acids concentrations

Amino acids were separated using one-column system, 3 x 200 mm, filled with joint resin OSTION LG FA (Ingos Prague, The Czech Republic). For the separation of amino acids, five lithium citrate buffers were used at pH - 2.9; 3.1; 3.35; 4.05; 4.90. The eluted amino acids were transferred into the tephlo-coated capillary and reacted with the incoming ninhydrin forming colored compounds. Amino acids were identified by retention time compared to the standards. Acidic and alkaline amino acids were separated at 38-39°C, and neutral amino acids at 59-60°C. Amino acid serum concentrations were expressed in micromoles per 1 cm<sup>3</sup> (μmol/cm<sup>3</sup>).

### Statistical analysis.

The results were statistically analysed and presented as tables and graphs. The investigated variables of the examined population were expressed as arithmetic means, and the minimum and maximum values and standard deviation. The differences between specified categories were calculated by statistical tests, the selection of which was determined by the level of measurement of the variables. The differences between the variables were determined using Student's t-test;  $p < 0.05$  was considered statistically significant [12].

## RESULTS

The maintenance of the normal concentration of plasma amino acids depends on the balance between amino acids supplied and used up by the body. Each disease causes disorders of various extent in the homeostasis of the body. The cardiac muscle becomes weakened by myocardial infarction, and simultaneously exerts a considerable effect on the functioning of the whole body. The determination and comparison of the levels of free amino acids in the blood plasma of the patients with MI was the object of the presented study.

Table 3 presents mean concentrations of the examined AAs in the groups of patients, minimum and maximum range, and standard deviation.

Table 3. Concentrations of free amino acids in the blood serum of patients with MI [μmol/cm<sup>3</sup>].

|                |     | patients aged < 65 yrs |       |       |       |       |       |       |       | patients aged ≥ 65 yrs |       |       |       |       |       |       |       |
|----------------|-----|------------------------|-------|-------|-------|-------|-------|-------|-------|------------------------|-------|-------|-------|-------|-------|-------|-------|
|                |     | Day 0                  |       | Day 1 |       | Day 3 |       | Day 7 |       | Day 0                  |       | Day 1 |       | Day 3 |       | Day 7 |       |
|                |     | M                      | SD    | M     | SD    | M     | SD    | M     | SD    | M                      | SD    | M     | SD    | M     | SD    | M     | SD    |
| alkaline       | LYS | 0.181                  | 0.037 | 0.199 | 0.032 | 0.234 | 0.066 | 0.230 | 0.345 | 0.182                  | 0.051 | 0.164 | 0.035 | 0.199 | 0.026 | 0.212 | 0.025 |
|                | HIS | 0.080                  | 0.014 | 0.089 | 0.017 | 0.088 | 0.021 | 0.086 | 0.019 | 0.076                  | 0.015 | 0.072 | 0.014 | 0.079 | 0.023 | 0.080 | 0.015 |
|                | ARG | 0.074                  | 0.200 | 0.065 | 0.016 | 0.116 | 0.062 | 0.099 | 0.039 | 0.079                  | 0.058 | 0.040 | 0.017 | 0.058 | 0.014 | 0.083 | 0.031 |
| acidic         | ASP | 0.040                  | 0.009 | 0.046 | 0.015 | 0.046 | 0.019 | 0.049 | 0.016 | 0.041                  | 0.009 | 0.036 | 0.010 | 0.042 | 0.011 | 0.037 | 0.009 |
|                | GLU | 0.352                  | 0.187 | 0.345 | 0.173 | 0.396 | 0.198 | 0.362 | 0.169 | 0.308                  | 0.183 | 0.295 | 0.169 | 0.322 | 0.189 | 0.345 | 0.153 |
| sulphuric      | MET | 0.018                  | 0.004 | 0.017 | 0.006 | 0.025 | 0.007 | 0.023 | 0.006 | 0.017                  | 0.006 | 0.020 | 0.009 | 0.021 | 0.004 | 0.022 | 0.006 |
| aromatic       | TYR | 0.086                  | 0.023 | 0.088 | 0.016 | 0.093 | 0.027 | 0.090 | 0.023 | 0.080                  | 0.024 | 0.071 | 0.014 | 0.082 | 0.020 | 0.080 | 0.027 |
|                | PHE | 0.065                  | 0.012 | 0.074 | 0.010 | 0.083 | 0.020 | 0.074 | 0.016 | 0.068                  | 0.024 | 0.065 | 0.017 | 0.072 | 0.013 | 0.069 | 0.010 |
| branched-chain | VAL | 0.233                  | 0.043 | 0.255 | 0.047 | 0.321 | 0.116 | 0.291 | 0.078 | 0.314                  | 0.169 | 0.274 | 0.085 | 0.292 | 0.088 | 0.264 | 0.054 |
|                | ILE | 0.062                  | 0.015 | 0.065 | 0.026 | 0.105 | 0.035 | 0.098 | 0.030 | 0.084                  | 0.031 | 0.077 | 0.028 | 0.093 | 0.019 | 0.087 | 0.016 |
|                | LEU | 0.123                  | 0.025 | 0.155 | 0.024 | 0.217 | 0.088 | 0.200 | 0.072 | 0.163                  | 0.080 | 0.152 | 0.040 | 0.176 | 0.043 | 0.162 | 0.024 |
| non-protein    | TAU | 0.076                  | 0.032 | 0.072 | 0.038 | 0.087 | 0.049 | 0.089 | 0.044 | 0.066                  | 0.033 | 0.077 | 0.041 | 0.074 | 0.043 | 0.078 | 0.032 |
|                | ORN | 0.089                  | 0.022 | 0.101 | 0.022 | 0.099 | 0.023 | 0.099 | 0.017 | 0.096                  | 0.021 | 0.078 | 0.022 | 0.086 | 0.017 | 0.091 | 0.019 |
|                | CIT | 0.036                  | 0.018 | 0.024 | 0.017 | 0.019 | 0.016 | 0.020 | 0.012 | 0.028                  | 0.018 | 0.017 | 0.008 | 0.020 | 0.009 | 0.022 | 0.005 |
| small protein  | SER | 0.110                  | 0.021 | 0.124 | 0.029 | 0.149 | 0.039 | 0.135 | 0.023 | 0.111                  | 0.032 | 0.106 | 0.032 | 0.135 | 0.022 | 0.118 | 0.017 |
|                | GLY | 0.214                  | 0.060 | 0.225 | 0.059 | 0.241 | 0.086 | 0.275 | 0.093 | 0.207                  | 0.063 | 0.188 | 0.034 | 0.232 | 0.054 | 0.258 | 0.076 |
|                | ALA | 0.402                  | 0.080 | 0.389 | 0.102 | 0.396 | 0.114 | 0.490 | 0.260 | 0.383                  | 0.096 | 0.356 | 0.131 | 0.338 | 0.081 | 0.403 | 0.090 |
|                | THR | 0.130                  | 0.037 | 0.146 | 0.046 | 0.181 | 0.083 | 0.181 | 0.051 | 0.133                  | 0.038 | 0.120 | 0.030 | 0.180 | 0.049 | 0.164 | 0.046 |

The values of concentrations of free AAs in the blood plasma of patients with MI in the age group < 65 varied considerably, and were low on day 0 and day 1. On subsequent days, these levels were within the norm or higher. The concentrations of free AAs in the blood plasma of patients with MI aged ≥ 65 varied considerably during the

whole period of study. The values of these amino acids most often remained below the reference value.

The results of Student's t- test (Tables 4-7) present the concentrations of free AAs in the blood plasma of patients in the groups aged < 65 years and ≥ 65 determined during the period of study.

Table 4. Concentrations of amino acids in the blood plasma of patients with MI ( $\mu\text{mol}/\text{cm}^3$ ) on day 0.

|               |     | Patients aged < 65yrs |       | Patients aged $\geq 65$ yrs |       | T      | p            |
|---------------|-----|-----------------------|-------|-----------------------------|-------|--------|--------------|
|               |     | M                     | SD    | M                           | SD    |        |              |
| alkaline      | LYS | 0.1805                | 0.037 | 0.1820                      | 0.051 | 0.017  | 0.898        |
|               | HIS | 0.0800                | 0.014 | 0.0761                      | 0.015 | 1.054  | 0.309        |
|               | ARG | 0.0738                | 0.200 | 0.0792                      | 0.058 | 0.202  | 0.655        |
| acidic        | ASP | 0.0397                | 0.009 | 0.0406                      | 0.009 | 0.141  | 0.708        |
|               | GLU | 0.3517                | 0.187 | 0.3077                      | 0.183 | 0.813  | 0.371        |
| sulphuric     | MET | 0.0180                | 0.004 | 0.0166                      | 0.006 | 0.969  | 0.329        |
| aromatic      | TYR | 0.0856                | 0.023 | 0.0795                      | 0.024 | 1.003  | 0.321        |
|               | PHE | 0.0648                | 0.012 | 0.0676                      | 0.024 | 0.352  | 0.555        |
| branch-chain  | VAL | 0.2325                | 0.043 | 0.3140                      | 0.169 | 6.946  | <b>0.011</b> |
|               | ILE | 0.0617                | 0.015 | 0.0837                      | 0.031 | 12.833 | <b>0.001</b> |
|               | LEU | 0.1232                | 0.025 | 0.1631                      | 0.080 | 7.169  | <b>0.010</b> |
| non-protein   | TAU | 0.0762                | 0.032 | 0.0659                      | 0.033 | 1.465  | 0.231        |
|               | ORN | 0.0890                | 0.022 | 0.0965                      | 0.021 | 1.822  | 0.182        |
|               | CIT | 0.0364                | 0.018 | 0.0278                      | 0.018 | 1.620  | 0.212        |
| small protein | SER | 0.1102                | 0.021 | 0.1112                      | 0.032 | 0.023  | 0.881        |
|               | GLY | 0.2135                | 0.060 | 0.2071                      | 0.063 | 0.164  | 0.687        |
|               | ALA | 0.4020                | 0.080 | 0.3829                      | 0.096 | 0.706  | 0.404        |
|               | THR | 0.1297                | 0.037 | 0.1332                      | 0.038 | 0.130  | 0.720        |

On day 0, statistically significantly higher levels of VAL, ILE, LEU were observed in the group aged  $\geq 65$  (Table 4).

Table 5. Concentrations of amino acids in the blood plasma of patients with MI ( $\mu\text{mol}/\text{cm}^3$ ) on day 1.

|               |     | Patients aged < 65yrs |       | Patients aged $\geq 65$ yrs |       | T      | p            |
|---------------|-----|-----------------------|-------|-----------------------------|-------|--------|--------------|
|               |     | M                     | SD    | M                           | SD    |        |              |
| alkaline      | LYS | 0.1986                | 0.032 | 0.1638                      | 0.035 | 16.473 | <b>0.000</b> |
|               | HIS | 0.0892                | 0.017 | 0.0722                      | 0.014 | 18.103 | <b>0.000</b> |
|               | ARG | 0.0654                | 0.016 | 0.0400                      | 0.017 | 24.216 | <b>0.000</b> |
| acidic        | ASP | 0.0463                | 0.015 | 0.0363                      | 0.010 | 8.616  | <b>0.005</b> |
|               | GLU | 0.3447                | 0.173 | 0.2950                      | 0.169 | 1.228  | 0.272        |
| sulphur       | MET | 0.0173                | 0.006 | 0.0201                      | 0.009 | 2.178  | 0.145        |
| aromatic      | TYR | 0.0885                | 0.016 | 0.0706                      | 0.014 | 20.599 | <b>0.000</b> |
|               | PHE | 0.0743                | 0.010 | 0.0645                      | 0.017 | 7.757  | <b>0.007</b> |
| branch-chain  | VAL | 0.2549                | 0.047 | 0.2738                      | 0.085 | 1.205  | 0.277        |
|               | ILE | 0.0654                | 0.026 | 0.0773                      | 0.028 | 2.879  | 0.095        |
|               | LEU | 0.1546                | 0.024 | 0.1519                      | 0.040 | 0.109  | 0.742        |
| non-protein   | TAU | 0.0719                | 0.038 | 0.0770                      | 0.041 | 0.258  | 0.613        |
|               | ORN | 0.1011                | 0.022 | 0.0777                      | 0.022 | 15.595 | <b>0.000</b> |
|               | CIT | 0.0243                | 0.017 | 0.0167                      | 0.008 | 3.957  | 0.053        |
| small protein | SER | 0.1239                | 0.029 | 0.1064                      | 0.032 | 5.113  | <b>0.027</b> |
|               | GLY | 0.2255                | 0.059 | 0.1877                      | 0.034 | 9.056  | <b>0.004</b> |
|               | ALA | 0.3892                | 0.102 | 0.3563                      | 0.131 | 1.204  | 0.277        |
|               | THR | 0.1462                | 0.046 | 0.1203                      | 0.030 | 6.561  | <b>0.013</b> |

On day 1, in the age group < 65 the values of concentrations of free AAs: LYS, HIS, ARG, ASP, TYR, PHE and ORN, SER, GLY, THR were statistically significantly higher in comparison to the age group  $\geq 65$ . Other differences were statistically insignificant (Table 5).

Table 6. Concentrations of amino acids in the blood plasma of patients with MI ( $\mu\text{mol}/\text{cm}^3$ ) on day 3.

|               |     | Patients aged < 65yrs |       | Patients aged $\geq 65$ yrs |       | T      | p            |
|---------------|-----|-----------------------|-------|-----------------------------|-------|--------|--------------|
|               |     | M                     | SD    | M                           | SD    |        |              |
| alkaline      | LYS | 0.2336                | 0.066 | 0.1987                      | 0.026 | 6.939  | <b>0.011</b> |
|               | HIS | 0.0884                | 0.021 | 0.0794                      | 0.023 | 2.658  | 0.108        |
|               | ARG | 0.1158                | 0.062 | 0.0581                      | 0.014 | 15.147 | <b>0.000</b> |
| acidic        | ASP | 0.0458                | 0.019 | 0.0416                      | 0.011 | 1.069  | 0.305        |
|               | GLU | 0.3958                | 0.198 | 0.3223                      | 0.189 | 2.133  | 0.149        |
| sulphur       | MET | 0.0248                | 0.007 | 0.0213                      | 0.004 | 5.184  | <b>0.026</b> |
| aromatic      | TYR | 0.0935                | 0.027 | 0.0818                      | 0.020 | 3.592  | 0.063        |
|               | PHE | 0.0830                | 0.020 | 0.0725                      | 0.013 | 5.972  | <b>0.017</b> |
| branch-chain  | VAL | 0.3207                | 0.116 | 0.2917                      | 0.088 | 1.189  | 0.280        |
|               | ILE | 0.1054                | 0.035 | 0.0929                      | 0.019 | 2.845  | 0.097        |
|               | LEU | 0.2171                | 0.088 | 0.1756                      | 0.043 | 5.190  | <b>0.026</b> |
| non-protein   | TAU | 0.0872                | 0.049 | 0.0740                      | 0.043 | 1.267  | 0.265        |
|               | ORN | 0.0995                | 0.023 | 0.0857                      | 0.017 | 6.666  | <b>0.012</b> |
|               | CIT | 0.0190                | 0.016 | 0.0203                      | 0.009 | 0.125  | 0.725        |
| small protein | SER | 0.1488                | 0.039 | 0.1345                      | 0.022 | 3.050  | 0.086        |
|               | GLY | 0.2407                | 0.086 | 0.2321                      | 0.054 | 0.210  | 0.648        |
|               | ALA | 0.3964                | 0.114 | 0.3376                      | 0.081 | 5.282  | <b>0.025</b> |
|               | THR | 0.1810                | 0.083 | 0.1798                      | 0.049 | 0.005  | 0.946        |

On day 3, the concentrations of LYS, ARG, MET, PHE and LEU, ORN, ALA were statistically significantly higher in the group < 65 compared to the group  $\geq 65$ . The remaining AA levels were not statistically significantly different between the groups. (Table 6).

Table 7. Concentrations of amino acids in the blood plasma of patients with MI ( $\mu\text{mol}/\text{cm}^3$ ) on day 7.

|               |     | Patients aged < 65yrs |       | Patients aged $\geq 65$ yrs |       | T     | p            |
|---------------|-----|-----------------------|-------|-----------------------------|-------|-------|--------------|
|               |     | M                     | SD    | M                           | SD    |       |              |
| alkaline      | LYS | 0.2298                | 0.345 | 0.2123                      | 0.025 | 4.396 | <b>0.041</b> |
|               | HIS | 0.0857                | 0.019 | 0.0804                      | 0.015 | 1.247 | 0.269        |
|               | ARG | 0.0993                | 0.039 | 0.0833                      | 0.031 | 2.046 | 0.160        |
| acidic        | ASP | 0.0489                | 0.016 | 0.0373                      | 0.009 | 9.935 | <b>0.003</b> |
|               | GLU | 0.3623                | 0.169 | 0.3453                      | 0.153 | 0.142 | 0.708        |
| sulphuric     | MET | 0.0234                | 0.006 | 0.0217                      | 0.006 | 1.091 | 0.301        |
| aromatic      | TYR | 0.0904                | 0.023 | 0.0802                      | 0.027 | 2.413 | 0.126        |
|               | PHE | 0.0743                | 0.016 | 0.0690                      | 0.010 | 2.112 | 0.152        |
| branch-chain  | VAL | 0.2907                | 0.078 | 0.2644                      | 0.054 | 2.033 | 0.159        |
|               | ILE | 0.0975                | 0.030 | 0.0867                      | 0.016 | 2.639 | 0.110        |
|               | LEU | 0.2003                | 0.072 | 0.1618                      | 0.024 | 6.453 | <b>0.014</b> |
| non-protein   | TAU | 0.0891                | 0.044 | 0.0780                      | 0.032 | 1.104 | 0.298        |
|               | ORN | 0.0989                | 0.017 | 0.0906                      | 0.019 | 2.897 | 0.095        |
|               | CIT | 0.0195                | 0.012 | 0.0222                      | 0.005 | 0.960 | 0.333        |
| small protein | SER | 0.1347                | 0.023 | 0.1182                      | 0.017 | 9.005 | <b>0.004</b> |
|               | GLY | 0.2754                | 0.093 | 0.2580                      | 0.076 | 0.576 | 0.451        |
|               | ALA | 0.4900                | 0.260 | 0.4031                      | 0.090 | 2.463 | 0.122        |
|               | THR | 0.1813                | 0.051 | 0.1643                      | 0.046 | 1.732 | 0.193        |

On Day 7, statistically significant differences between the groups were observed only in the case of LYS, ASP, and LEU and SER. In all cases, the level of the above-mentioned AAs was statistically significantly higher in the age group < 65. Other values were not statistically significantly different between the groups (Table 7).






Figure 1. Analysis of the level of amino acids in blood plasma of patients with myocardial infarction. The data presented as the mean and standard deviation (n=60; \* -  $p < 0.05$ ; \*\* -  $p < 0.01$ ; \*\*\* -  $p < 0.001$ ; t-Student test).

## DISCUSSION

Cardiovascular diseases are the leading causes of mortality, and are responsible for nearly 50% of all deaths. The main cardiovascular diseases include the complication of ischemic heart disease, e.g. myocardial infarction, and cerebrovascular diseases, which are the cause of 35% of all deaths in Europe. However, considerable differences between individual countries are observed with respect to such indicators as age, gender, and distribution of the conditioning factors. [26]

Clinical symptoms of acute coronary syndrome (ACS) occur in nearly 30% of individuals aged over 65. In developed countries, it remains the most frequent cause of deaths among males aged over 45, and females aged over 65. In the population of the elderly, females are a considerably higher percentage of patients with ACS. Cardiovascular diseases are often accompanied by other disorders, such as arterial hypertension or diabetes. In the aetiology of myocardial infarction dynamic changes develop within the blood vessels. With time the changes narrow vascular lumen, and sometimes even occlude the vessel completely [11].

In the course of a coronary event acute-phase proteins increase considerably [23]. In the situation of oxygen deficiency there is an insufficient blood flow to the tissues. This causes an enhanced protein catabolism and change in the AA profile. These disorders are observed in MI. On the cellular level, that results in anaerobic metabolism, and resultant metabolic acidosis. It impairs the function of cells and may even lead to their irreversible damage. The conducted studies showed variations in the free AA profile in the blood plasma of the patients from the moment of admission to hospital until day 7 of hospitalization. The concentration of free AAs in the plasma of patients with MI varied according to the duration of treatment. On day 0, a significantly statistically higher level of VAL, ILE, LEU was observed in patients aged 65 and older.

On day 1 of hospitalization, statistically significant differences in the concentrations of LYS, HIS, ARG, ASP, TYR, PHE and ORN, SER, GLY, THR were observed between the groups of examined patients. In cases of the aforementioned AAs the values were higher in the group aged < 65. The concentration of other AAs were not statistically significantly different. However, on day 3 of hospitalization, the concentrations of LYS, ARG, MET, PHE and LEU, ORN, ALA were statistically significantly higher in the group aged < 65.

No statistically significant differences were found with respect to the remaining amino acids. On day 7 of hospitalization, statistically significant differences in the values of LYS, ASP and LEU and SER were recorded between the groups of the examined patients. The level of those AAs was higher in the group < 65. Other values were statistically insignificant between the groups.

Bertolini et al. [2] observed the effect of age and gender on the levels of amino acids in human blood. Also, Armstrong [1], who conducted studies on a large population, indicated a lower level of free amino acids in the plasma of females. The importance of transformations of amino acids in the pathogenesis of many diseases has been noted in recent years. The results helped introduce new analytical methods to determine the concentrations of free amino acids in the body fluids.

Górski et al. [7] presented the most important data concerning the use of energy substrates by the healthy heart muscle in ischemic disease and diabetes. The heart muscle possesses a unique capacity to use various energy substrates and immediately convert them. It may use energy from glucose, free fatty acids, lactic acid, and ketone bodies. The heart muscle may use some amino acids as energy substrates, including glutamine, glutamic acid, as well as aspartic acid, and alanine.

Moreover, there is a need to conduct research into amino acid metabolism in obesity, considering the fact that an increased level of free amino acids in the plasma may stimulate the secretion of insulin. Studies by Zwaigzne et al. [32] confirmed the extent and effect of the reduction of body weight as a result of weight loss treatment on the concentration of free amino acids in the plasma and blood cells. The researchers found the concentration of free amino acids in the blood plasma and red blood cells in obese children changed together with weight loss. Their levels were close to the values of free amino acids in the children with normal body weight [19]. Observations by other researchers indicate that there is a further need to investigate amino acids metabolism in obesity. The results of studies confirm the presence of changes in protein metabolism in obese children.

In their study, Hżęcka et al. [10] determined the concentration of amino acids in the plasma of patients with atherosclerosis. They found that amino acids may play an important role in the etiology of the disease. The concentrations of amino acids varied. In the whole group, considerably decreased values of isoleucine, leucine,

tyrosine, and valine were observed. The clinical status of patients concerning severe atherosclerotic burden exerted a significant effect on the levels of amino acids, with the highest concentrations of alanine observed in terminal patients. Nevertheless, no statistically significant relationship was found with concomitant diseases, or between the clinical pathological symptoms of these diseases and duration of the disease.

Changes in free amino acid profile in the plasma of patients in acute coronary syndromes result from disorders developing in the body due to pathological processes. In the course of an acute coronary event, acute-phase proteins increase considerably [20]. In the situation of acute oxygen deficiency, the tissue blood flow is insufficient. It causes enhanced protein catabolism and changed amino acid profile. On the cellular level, anaerobic metabolism develops, leading to metabolic acidosis. It impairs the function of cells and may even lead to their irreversible damage. In physiological conditions, the concentrations of free amino acids depend on many factors, such as gender, age, nutrition, intensity of physical activity and the state of health. In order to maintain undisturbed synthesis of all body proteins, a positive nitrogen balance is necessary, which is possible only when the human body is in the state of health. In the course of myocardial infarction, free amino acids are used in a different way.

The results of our study revealed different free amino acid profile in the plasma of patients aged < 65 and ≥ 65 who had undergone myocardial infarction. The determination of aminogram and its interpretation may constitute a basis for the application of the supplementation of amino acids, which are the source of energy for the body cells.

#### CONCLUSIONS:

Myocardial infarction as a life threatening state causes dynamic changes in free amino acid profile; they are considerably more pronounced in patients aged under 65.

On day 0 in the group of patients aged 65 years and older the level of amino acids was statistically significantly higher, however it decreased during the rest of the observation period.

#### REFERENCES

1. Armstrong M.D., Stave U. (1973). Author links open the author workspace.D.: A study of plasma

- free amino acid levels. Normal values for children and adults. *Metabolism*. 22. p.561-563.
2. Bertolini A., M., Santagostino A., Belgioioso G., B. (1972). The behavior of free amino acids in the plasma of the aged. *Gerontol. Clin.* 14. p.43-49.
3. Brodzińska K. (1997). Physiology and pathology of oxygenation. *Anestezjol. Intens. Ter.* 29. p.149-256.
4. Cascino A. (1995). Plasma amino acid imbalance in patients with lung and breast cancer. *Anticancer Res.* 15. p.507-509.
5. Gajek J. (2003). Ostre zespoły wieńcowe a zakażenia Chlamydia pneumoniae. *Pol. Merk. Lek.* 85. p.20-23 [in Polish].
6. Giec L. (2000). Leczenie choroby niedokrwiennej serca. *Via Medica, Gdańsk* [in Polish].
7. Górski J., Knapp M., Musiał W. (2000). Metabolizm substratów energetycznych w mięśniu sercowym. Wpływ niedotlenienia i cukrzycy. *Czyn. Ryz.* 2/3. p.18-23 [in Polish].
8. Hjemdahl P. (2003). Stress and the metabolic syndrome: an interesting but enigmatic association. *Circulation*. 106(21). p. 2634-6.
9. Hoffman A., Sienkiewicz W., Dowgiłowicz-Nowicka M. (2000). Coronary artery disease in women – ongoing problematical diagnostic issue. *Pol. Arch. Med. Wewn.* 2. p.501-506.
10. Iłżecka J., Stelmasiak Z., Solski J., Wawrzynski S., Szpetnar M. (2003). Plasma amino acids concentration in amyotrophic lateral sclerosis patients. *Amino Acids*. 25. p.69-73.
11. Janion M., Woźakowska-Kapłon B., Sadowski J. (2004). Cardiac rupture in acute myocardial infarction with ST segment elevation. *Kardiologia Pol.* 61. p.127-131.
12. Jędrychowski W., Penar A. (2000). Statystyczna analiza wyniku badań naukowych w medycynie i biologii. *Wyd. UJ, Kraków* [in Polish].
13. Kierus A., Żebrowski R. (2000). The molecular mechanisms of myocardial infarction. *Klinika*. 7 (10). p.1013-1016.
14. Kokot F. (2002). Choroby wewnętrzne. *PZWL, Warszawa* [in Polish].
15. Kumar S. (2006). Progress in the treatment of multiple myeloma. *Lancet*. p.367-791.
16. Lazarewicz J. (2000). Pobudzające aminokwasy w niedokrwieniu mózgu. *Farm. Pol.* 56 (10). p.476-487 [in Polish].
17. Malczewska B., Chotkowska E., Szwed H., Sadowski Z. (2001). Risk factor of coronary heart disease in women. *Pol. Arch. Med. Wewn.* 1. p.79-83.
18. Mark D. B. (2005). Efektywność kosztowa prewencji chorób układu krążenia. [W:] Yusuf S., Cairnes J.A., Camm J.: Kardiologia faktów. Evidence based. *T. I. Centr. Wyd. Med.* p.372-383 [in Polish].

19. Modi P., Suleiman S. M., Reeves B. C., Pawade A., Parry A. J., Angelini G.D., Caputo M. (2006). Changes in myocardial free amino acids during pediatric cardiac surgery: a randomised controlled trial of three cardioplegic techniques. *Eur. J. Cardiovasc. Surg.* 30. p.41-48.
20. Murray R.K., Granner D. K., Mayes P. A., Rodwell V. W. (1995). Biochemia Harpera. PZWL, Warszawa [in Polish].
21. Nowacka A., Gawęł G., Rak A., Piórecka B. (2003). Styl życia pacjentów po pierwszym zawałe serca a czynniki ryzyka choroby niedokrwiennej serca. *Ann. UMCS, Sect. D.* 173. p.375-381 [in Polish].
22. Puźniak A., Dzida G., Kraczkowski T., Gałęziok M., Sobstyl J., Hanzlik J. (2002). Polimorfizm genu ludzkiego receptora insuliny (hINSR) u chorych z zawałem serca. *Pol. Merk. Lek.* 74. p.137-139 [in Polish].
23. Ravel R. (1989). Clinical Laboratory medicine. Clinical application of laboratory data. *Year Book Med. Pub. Inc. London.*
24. Rogers W.J., Canto J.G., Barron H.V., Boscarino J.A., Shoultz D.A. Every N.R. (2000). Porównanie leczenia zawału mięśnia sercowego i rokowania pacjentów w szpitalach dysponujących metodami inwazyjnymi i w szpitalach nie mających takich możliwości. *JACC - Wyd. Pol.* 1 (3). p.227-237 [in Polish].
25. Rourke R. A., Hochmann J. S., Cohen M. C. Lucore C. L., Cannon C.P. (2001). Nowe zasady postępowania diagnostycznego i leczniczego w niestabilnej dławicy piersiowej i zawałe mięśnia sercowego bez uniesienia odcinka ST. *JAMA - Wyd. Pol.* 3 (7). p.525-536 [in Polish].
26. Zdrojewski T., Bandosz P., Szpakowski P. et al. (2004). Rozpowszechnienie głównych czynników ryzyka chorób układu sercowo - naczyniowego w Polsce. Wyniki badania NATPOL PLUS. *Kardiol. Pol.* 61 (supl.4). p.5-25 [in Polish].
27. Rużyłko W., Karcz M. (2003). Inwazyjne leczenie ostrych zespołów wieńcowych w Polsce: jakie było w 2002 roku, jakie może i powinno być w latach następnych? *Kardiol. Pol.* 58. p.5-12 [in Polish].
28. Rybarczyk H., Sanak M., Szczeklik A. (2001). Enzymes conjugated with glutathione and their importance in medicine. *Pol. Arch. Med. Wewn.* 6. p.517-523.
29. Rzetecka K., Drożdż J., Gozik P., Kosztelowicz P., Kasprzak J., Stępińska J., Krzemińska-Pukała M., Różyłka W., Wysocki H. (2001). Clinical outcomes of acute myocardial infarction in elderly patients – result of POL-WEB-AMI trial (POLish multicenter WEB-based trial on Acute Myocardial Infarction). *Pol. Przegl. Kardiol.* 3 (4). p.283-289 [in Polish].
30. Skrzypek M. (2004). Low socioeconomic status as the social risk factor of coronary heart disease at the threshold of the 21 st century. *Pol. Przegl. Kardiol.* 6 (4). p.439-444.
31. Żebrowski R., Kierus A., Żebrowska A. (2000). The molecular processes in the pathogenesis of coronary artery disease. *Klinika* 7 (10). p.1031-1035.
32. Zwaigzne-Raczyńska J., Gołębiowska M. (1990). Zachowanie się wolnych aminokwasów w osoczu i krwinkach czerwonych u dzieci z otyłością prostą pod wpływem leczenia odchudzającego. *Pediatr. Pol.* 65 (11/12). p.16-23. [in Polish].